Geochemistry and evolution of groundwater resources in the context of salinization and freshening in the southernmost Mekong Delta, Vietnam

Study region Ca Mau Province (CMP), Mekong Delta (MD), Vietnam. Study focus Groundwater from deep aquifers is the most reliable source of freshwater in the MD but extensive overexploitation in the last decades led to the drop of hydraulic heads and negative environmental impacts. Therefore, a comprehensive groundwater investigation was conducted to evaluate its composition in the context of Quaternary marine transgression and regression cycles, geochemical processes as well as groundwater extraction. New hydrological insights for the region The abundance of groundwater of Na-HCO$_{3}$ type and distinct ion ratios, such as Na$^{+}$/Cl$^{-}$, indicate extensive freshwater intrusion in an initially saline hydrogeological system, with decreasing intensity from upper Pleistocene to deeper Miocene aquifers, most likely during the last marine regression phase 60–12 ka BP. Deviations from the conservative mixing line between the two endmembers seawater and freshwater are attributed to ion-exchange processes on mineral surfaces, making ion ratios in combination with a customized water type analysis a useful tool to distinguish between salinization and freshening processes. Elevated salinity in some areas is attributed to HCO$_{3}$$^{-}$ generation by organic matter decomposition in marine sediments rather than to seawater intrusion. Nevertheless, a few randomly distributed locations show strong evidence of recent salinization in an early stage, which may be caused by the downwards migration of saline Holocene groundwater through natural and anthropogenic pathways into deep aquifers

An Improved Groundwater Model Framework for Aquifer Structures of the Quaternary-Formed Sediment Body in the Southernmost Parts of the Mekong Delta, Vietnam

The Ca Mau peninsula (CMP) is a key economic region in southern Vietnam. In recent decades, the high demand for water has increased the exploitation of groundwater, thus lowering the groundwater level and leading to risks of degradation, depletion, and land subsidence, as well as salinity intrusion in the groundwater of the whole Mekong Delta region. By using a finite element groundwater model with boundary expansion to the sea, we updated the latest data on hydrogeological profiles, groundwater levels, and exploitation. The basic model setup covers seven aquifers and seven aquitards. It is determined that the inflow along the coastline to the mainland is 39% of the total inflow. The exploitation of the study area in 2019 was 567,364 m3/day. The most exploited aquifers are the upper-middle Pleistocene (qp2–3) and the middle Pliocene (n22), accounting for 63.7% and 24.6%, respectively; the least exploited aquifers are the upper Pleistocene and the upper Miocene, accounting for 0.35% and 0.02%, respectively. In the deeper aquifers, qp2–3 and n22, the change in storage is negative due to the high exploitation rate, leading to a decline in the reserves of these aquifers. These groundwater model results are the calculations of groundwater reserves from the coast to the mainland in the entire system of aquifers in the CMP. This makes groundwater decision managers, stakeholders, and others more efficient in sustainable water resources planning in the CMP and Mekong Delta (MKD)

Crystallization and preliminary X-ray analysis of neoagarobiose hydrolase from Saccharophagus degradans 2-40

Many agarolytic bacteria degrade agar polysaccharide into the disaccharide unit neoagarobiose [O-3,6-anhydro-α-L-galactopyranosyl-(1→3)-D-galactose] using various β-agarases. Neoagarobiose hydrolase is an enzyme that acts on the α-1,3 linkage in neoagarobiose to yield D-galactose and 3,6-anhydro-L-galactose. This activity is essential in both the metabolism of agar by agarolytic bacteria and the production of fermentable sugars from agar biomass for bioenergy production. Neoagarobiose hydrolase from the marine bacterium Saccharophagus degradans 2-40 was overexpressed in Escherichia coli and crystallized in the monoclinic space group C2, with unit-cell parameters a = 129.83, b = 76.81, c = 90.11 Å, β = 101.86°. The crystals diffracted to 1.98 Å resolution and possibly contains two molecules in the asymmetric unit

Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.There are no data on the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with acute myeloid leukemia (AML). The NOPHO-AML 2004 protocol studied postconsolidation randomization to GO or no further therapy. GO was administered at 5 mg/m(2) and repeated after 3 weeks. We randomized 120 patients; 59 to receive GO. Survival was analyzed on an intention-to-treat basis. The median follow-up for patients who were alive was 4.2 years. Children who received GO showed modest elevation of transaminase and bilirubin without signs of veno-occlusive disease. Severe neutropenia followed 95% and febrile neutropenia 40% of the GO courses. Only a moderate decline in platelet count and a minor decrease in hemoglobin occurred. Relapse occurred in 24 and 25 of those randomized to GO or no further therapy. The median time to relapse was 16 months versus 10 months (nonsignificant). The 5-year event-free survival and overall survival was 55% versus 51% and 74% versus 80% in those randomized to receive GO or no further therapy, respectively. Results were similar in all subgroups. In conclusion, GO therapy postconsolidation as given in this trial was well tolerated, showed a nonsignificant delay in time to relapse, but did not change the rate of relapse or survival (clinicaltrials.gov identifier NCT00476541).Swedish Childhood Cancer Foundation Danish Childhood Cancer Foundation Karen Elise Jensen Foundation Wyet

Tubular and Glomerular Kidney Effects in Swedish Women with Low Environmental Cadmium Exposure

Cadmium is a well-known nephrotoxic agent in food and tobacco, but the exposure level that is critical for kidney effects in the general population is not defined. Within a population-based women’s health survey in southern Sweden (Women’s Health in the Lund Area, WHILA), we investigated cadmium exposure in relation to tubular and glomerular function, from 1999 through early 2000 in 820 women (71% participation rate) 53–64 years of age. Multiple linear regression showed cadmium in blood (median, 0.38 μg/L) and urine (0.52 μg/L; density adjusted = 0.67 μg/g creatinine) to be significantly associated with effects on renal tubules (as indicated by increased levels of human complex-forming protein and N-acetyl-β-d-glucosaminidase in urine), after adjusting for age, body mass index, blood lead, diabetes, hypertension, and regular use of nephrotoxic drugs. The associations remained significant even at the low exposure in women who had never smoked. We also found associations with markers of glomerular effects: glomerular filtration rate and creatinine clearance. Significant effects were seen already at a mean urinary cadmium level of 0.6 μg/L (0.8 μg/g creatinine). Cadmium potentiated diabetes-induced effects on kidney. In conclusion, tubular renal effects occurred at lower cadmium levels than previously demonstrated, and more important, glomerular effects were also observed. Although the effects were small, they may represent early signs of adverse effects, affecting large segments of the population. Subjects with diabetes seem to be at increased risk

Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01

Background Supportive-care use of granulocyte colony-stimulating factor (G-CSF) in pediatric acute myeloid leukemia (AML) remains controversial due to a theoretical increased risk of relapse and limited impact on neutropenic complications. We describe the use of G-CSF in patients treated according to NOPHO-AML 2004 and DB AML-01 and investigated associations with relapse. Procedure Patients diagnosed with de novo AML completing the first week of therapy and not treated with hematopoietic stem cell transplantation in the first complete remission were included (n = 367). Information on G-CSF treatment after each course (yes/no) was registered prospectively in the study database and detailed information was gathered retrospectively from each center. Descriptive statistics were used to describe G-CSF use and Cox regression to assess the association between G-CSF and risk of relapse. Results G-CSF as supportive care was given to 128 (35%) patients after 268 (39%) courses, with a large variation between centers (0-93%). The use decreased with time-the country-adjusted odds ratio was 0.8/diagnostic year (95% confidence interval [CI] 0.7-0.9). The median daily dose was 5 mu g/kg (range 3-12 mu g/kg) and the median cumulative dose was 75 mu g/kg (range 7-1460 mu g/kg). Filgrastim was used in 82% of G-CSF administrations and infection was the indication in 44% of G-CSF administrations. G-CSF was associated with increased risk of relapse-the adjusted hazard ratio was 1.5 (95% CI 1.1-2.2). Conclusions G-CSF as supportive care was used in a third of patients, and use decreased with time. Our results indicate that the use of G-CSF may be associated with an increased risk of relapse.Peer reviewe